Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyaluronidase for perforator flap tissue perfusion
NL-OMON53369Phase 3Withdrawn
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2023
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hyaluronidase in hypoperfusion and flap failure, sponsored by Leiden University Medical Center. Primary endpoint: Primary: tissue perfusion of the perforator flap. Planned start Feb 2023; status: withdrawn.
02
Drugs
hyaluronidase
03
Conditions
hypoperfusionflap failure
Beyond the preview
Go deeper on NL-OMON53369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53369.